Rhythm Pharmaceuticals (RYTM) EBIT (2020 - 2025)
Historic EBIT for Rhythm Pharmaceuticals (RYTM) over the last 6 years, with Q3 2025 value amounting to -$52.7 million.
- Rhythm Pharmaceuticals' EBIT fell 1997.95% to -$52.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$186.2 million, marking a year-over-year increase of 2986.91%. This contributed to the annual value of -$265.5 million for FY2024, which is 4401.57% down from last year.
- Per Rhythm Pharmaceuticals' latest filing, its EBIT stood at -$52.7 million for Q3 2025, which was down 1997.95% from -$45.3 million recorded in Q2 2025.
- In the past 5 years, Rhythm Pharmaceuticals' EBIT registered a high of -$34.4 million during Q1 2021, and its lowest value of -$139.9 million during Q1 2024.
- Over the past 5 years, Rhythm Pharmaceuticals' median EBIT value was -$44.2 million (recorded in 2021), while the average stood at -$49.7 million.
- As far as peak fluctuations go, Rhythm Pharmaceuticals' EBIT tumbled by 16629.42% in 2024, and later skyrocketed by 6639.86% in 2025.
- Over the past 5 years, Rhythm Pharmaceuticals' EBIT (Quarter) stood at -$51.0 million in 2021, then grew by 17.43% to -$42.1 million in 2022, then increased by 1.99% to -$41.3 million in 2023, then grew by 0.02% to -$41.3 million in 2024, then fell by 27.63% to -$52.7 million in 2025.
- Its last three reported values are -$52.7 million in Q3 2025, -$45.3 million for Q2 2025, and -$47.0 million during Q1 2025.